Illumina Launches New Genomic AI Model for Rare Disease Research
MT newswire2026/10/08 13:5509:55 AM EDT, 10/08/2026 (MT Newswires) -- Illumina (ILMN) said Thursday it launched new genomic AI model SpliceAI2 to support rare disease research projects. The new model allows researchers to identify disease-relevant splice variants, the company said. When applied to a rare disease research dataset, SpliceAI2 identified 17% more disease-relevant variants compared with other splicing models, Illumina said. SpliceAI2 may be accessed through the BioInsight applications, the company said. Illumina shares were down 3.9% in Thursday trading. Price: 257.30, Change: -10.46, Percent Change: -3.91
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny
CoreWeave will release its third-quarter financial report. Whether it can demonstrate that its rapid revenue growth is sufficient to cover the rising financing costs and construction expenditures will directly determine the direction of market confidence.
Crypto prices
More
